NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces $45.1M NINDS Grant to Support Expanded Access Protocol for CNM-Au8(R) in ALS
Clene (NASDAQ: CLNN), through its wholly owned subsidiary Clene Nanomedicine Inc. in collaboration with Columbia University and Synapticure, was awarded a four-year grant totaling $45.1 million from the National Institute of Neurological Disorders and Stroke (“NINDS”), a division of the National Institutes of Health (“NIH”). The grant is to support an Expanded Access Protocol (“EAP”) for the company’s investigational drug, CNM-Au8(R), in amyotrophic lateral sclerosis (“ALS”). Also referred to as Compassionate Use, an EAP is an FDA-regulated pathway that allows people with a serious and life-threatening disease to access an investigational drug that is not yet approved by the U.S.…
